Close mobile menu×
Close mobile menu

Lisa F. Imundo, MD

Board Certifications: 
Pediatric Rheumatology
Expertise in: 
Adolescent Rheumatology
Accepting New Patients
Treats Children
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-4308

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Pediatric Rheumatology

Clinical Expertise

  • Adolescent Rheumatology
  • Young Adults
  • Rheumatology
  • Adolescent Medicine
  • Pediatric Rheumatology
  • Kawasaki Disease
  • Scleroderma
  • Lyme Disease
  • Lupus
  • Arthritis

Specialties

Education & Training

  • State University of New York - Downstate Health Sciences Center
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

About Lisa Imundo

Lisa F. Imundo, MD - ColumbiaDoctors Rheumatologist

Dr. Imundo has 20 years of experience as a pediatric rheumatologist with a busy and complex clinic practice; she is engaged in clinical care, education, and research. Dr. Imundo is the founder and director of the Center for Adolescent Rheumatology, which provides care for children and adolescents with chronic rheumatic disease with a focus on helping teens and young adults become more prepared and independent to successfully transition from pediatric to adult care. Research demonstrates that despite having programs in place at pediatric centers, teens and young adults are not consistent in managing their diseases and have worse outcomes and increased medical complications. At the Center for Adolescent Rheumatology, pediatric and adult providers work together and collect data on effective ways to educate teens and measure teen readiness to become independent. New, innovative, disease-specific collaborative clinics staffed with pediatric and adult rheumatologists will help all families support their children and help them become prepared for transition.

Dr. Imundo's mentor Dr. Jerry Jacobs established Pediatric Rheumatology in 1960 at Columbia, under the mentorship of Charles Raean, the Chairman of Medicine, and Charles Christian,the Chairman of Adult Rheumatology. Dr. Jacobs wrote the first textbook in the field, "Pediatric Rheumatology for the Practitioner," and defined new entities which today have genetic, cellular, and molecular foundations. Dr. Jacobs' former fellows, among them Dr. Imundo, wrote the continuing textbook "Arthritis in Children and Adolescents" (I. Szer, ed.).

At Columbia University Dr. Imundo was appointed both Division Director and Fellowship Director shortly after completing her Chief Residency and Fellowship. Under her leadership, her Division of Pediatric Rheumatology (1997-2014) expanded to provide care for thousands of children with complex and often mysterious autoimmune and rheumatic diseases, both on the inpatient and on the outpatient service, a record unmatched in the USA. She continues in the footsteps of Dr. Jacobs defining new entities and conducting cutting-edge research in the efficacy of molecularly specific medications. Like Dr. Jacob's before her, Dr. Imundo is available continuously to treat the sick children of the tri-state area, and like Dr. Jacob's before her, Dr. Imundo's patients become part of her family, and she very frequently part of theirs.

Academic Titles

  • Associate Professor of Pediatrics (in Medicine) at CUMC

Administrative Positions

  • Director of Adolescent Rheumatology

Committee/Societies/Council Memberships

She currently represents Pediatric Rheumatology on the American Board of Pediatrics, the Committee of Pediatric Subspecialists and she is President of the American Academy of Pediatric Executive Committee on Pediatric Rheumatology.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • Komansky Center for Children's Health
  • NewYork-Presbyterian/Morgan Stanley Children's Hospital
  • NewYork-Presbyterian/Weill Cornell

Languages

  • Spanish

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • HMO
  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Healthfirst

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

POMCO

  • POMCO

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-4308
Primary
2
51 West 51st Street
New York, New York 10019
Phone:
(212) 305-4308
3
155 White Plains Road
Tarrytown, New York 10591
Phone:
(212) 305-4308

Research

Dr. Imundo's research involves finding more effective and less toxic regimens for treating children.  She has actively participated in over twenty-five medication trials to introduce new treatments for children with juvenile idiopathic arthritis, childhood onset lupus, vasculitis, and dermatomyositis. She has also participated in efforts to gather information about safety and effectiveness of medications already used to treat children – because children are not just little adults.

Dr. Imundo participates in several collaborative investigator initiated networks. These networks collect information across multiple centers and these collaborations lead to accelerated progress.

     - Pediatric Rheumatology Center Study Group (PRCSG) works to optimize studies being done by the pharmaceutical industry to obtain more FDA approved medications for children and adolescent patients.

     - Childhood Arthritis & Research Rheumatology Alliance (CARRA). This network has a long-term database to gather information about children with rheumatic disease and to gather information about outcomes. Pragmatic and observational trials are being initiated across this network.

     - International Myositis Outcomes Assessment Collaborative Study Group, and the Childhood Myositis Heterogeneity Collaborative Study Group

     - ARChiVe (A Registry for Childhood Vasculitis)

Dr. Imundo has also been involved with improving the field of pediatric rheumatology.  She led the American College of Rheumatology pediatric workforce/manpower study that highlighted the current shortage of pediatric rheumatologists and the looming crisis ahead for the United States as patients become less and less able to access care. Finally, the field of rheumatology has been changed and revolutionized and Dr. Imundo worked with several professional organizations including the American Board of Pediatrics to update the curriculum and professional standards for Board Certification.

Grants

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF 2 DOSE LEVELS OF SUBCUTANEOUS ANAKINRA (KINERET?) IN PATIENTS WITH STILL?S DISEASE (SJIA AND AOSD) (P&S Industry Clinical Trial)

Jan 23 2018 - Jan 23 2023

A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) (P&S Industry Clinical Trial)

Feb 23 2017 - Feb 23 2022

A PHASE IIA, INTERNATIONAL, MULTICENTER, OPEN LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF 4X375 MG/M2 INTRAVENOUS RITUXIMAB IN PEDIATRIC PATIENTS WITH SEVERE GRANULOMATOSIS WITH POLYAGIITIS (P&S Industry Clinical Trial)

Feb 20 2015 - Feb 20 2020

MULTI-CENTER, OPEN LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN CHILDREN AND ADOLESCENTS WITH MODERATELY TO SEVERLY ACTIVE POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (P&S Industry Clinical Trial)

May 8 2013 - May 8 2018

OBSERVATIONAL STUDY OF PEDIATRIC RHEUMATIC DISEASES: THE CARRA REGISTRY (Private)

Nov 4 2015 - Nov 3 2016

CHILDREN ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE (CARRA REGISTRY) (Private)

Sep 1 2012 - Aug 31 2015

MECHANISM OF B CELL RESPONSES IN AUTOIMMUNE : C13-ALE05-COU (Federal Gov)

May 1 2013 - Apr 30 2015

ETANERCEPT FOR ACUTE KAWASAKI DISEASE (Federal Gov)

Jun 1 2011 - May 31 2014

TOWARDS MEASURES OF LUPUS NEPHRITIS ACTIVITY & DAMAGE FOR CHILDREN (Federal Gov)

Aug 8 2010 - May 31 2014

IL-1 INHIBITION IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS, R ANDOMIZE, DOUBLE BLINDED PLACEBO CONTROLLED MULTICENTER TRIA (Federal Gov)

Jul 1 2008 - Dec 31 2012

CHILDHOOD ARTHRITIS AND RESEARCH ALLIANCE NETWORK (CARRANET) ACCELERATING TOWARD AND EVIDENCE BASED CULTURE IN PEDIATRIC (Federal Gov)

Feb 22 2011 - Aug 31 2012

ARTHEROSCLEROSIS PREVENTION IN PEDIATRIC LUPUS ERYTHEMATOSUS (Federal Gov)

Dec 1 2003 - Apr 30 2011

PHASE II IL-1 TRAP FOR TREATMENT OF FAMILIAL MEDITERRANEAN F EVER (Federal Gov)

Sep 29 2007 - Feb 28 2011

LUPUS BIOMARKS WORKING GROUP DATABASE (Private)

Feb 1 2006 - Dec 31 2010

TRIPTORELIN FOR OVARY PROTECTION IN CHILDHOOD LUPUS (Federal Gov)

Sep 30 2004 - Sep 29 2010

MULTICENTER PROSPECTIVE REGISTRY OF INFLIXIMAB USE IN RESIST ANT CHILDHOOD UVEITIS (Private)

Nov 12 2008 - Nov 11 2009